HC Wainwright Has Negative Outlook for PolyPid Q1 Earnings

PolyPid Ltd. (NASDAQ:PYPD) – Research analysts at HC Wainwright cut their Q1 2025 EPS estimates for shares of PolyPid in a note issued to investors on Monday, April 14th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.80) per share for the quarter, down from their previous forecast of ($0.74). HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for PolyPid’s Q2 2025 earnings at ($0.58) EPS, Q3 2025 earnings at ($0.42) EPS and FY2025 earnings at ($1.87) EPS.

PolyPid (NASDAQ:PYPD) last posted its earnings results on Wednesday, February 12th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.23).

A number of other research analysts also recently commented on the company. RODMAN&RENSHAW raised PolyPid to a “strong-buy” rating in a report on Tuesday, January 28th. Rodman & Renshaw started coverage on shares of PolyPid in a report on Tuesday, January 28th. They issued a “buy” rating and a $13.00 price target for the company.

PolyPid Price Performance

Shares of PYPD stock opened at $2.70 on Wednesday. The firm has a fifty day simple moving average of $2.82 and a 200-day simple moving average of $3.09. The company has a market capitalization of $27.52 million, a PE ratio of -0.54 and a beta of 1.28. PolyPid has a twelve month low of $2.30 and a twelve month high of $5.09. The company has a current ratio of 1.31, a quick ratio of 1.00 and a debt-to-equity ratio of 0.08.

Institutional Trading of PolyPid

A number of hedge funds have recently bought and sold shares of PYPD. J. Goldman & Co LP bought a new position in shares of PolyPid in the 4th quarter valued at approximately $391,000. Rosalind Advisors Inc. lifted its holdings in shares of PolyPid by 49.9% during the 4th quarter. Rosalind Advisors Inc. now owns 1,018,021 shares of the company’s stock worth $3,095,000 after acquiring an additional 338,853 shares during the period. Finally, AIGH Capital Management LLC boosted its holdings in PolyPid by 21.8% during the fourth quarter. AIGH Capital Management LLC now owns 827,867 shares of the company’s stock valued at $2,509,000 after purchasing an additional 148,199 shares in the last quarter. 26.47% of the stock is owned by hedge funds and other institutional investors.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.